Literature DB >> 25444993

Repair mechanisms help glioblastoma resist treatment.

Ryan J Atkins1, Wayne Ng2, Stanley S Stylli2, Christopher M Hovens3, Andrew H Kaye2.   

Abstract

Glioblastoma multiforme (GBM) is a malignant and incurable glial brain tumour. The current best treatment for GBM includes maximal safe surgical resection followed by concomitant radiotherapy and adjuvant temozolomide. Despite this, median survival is still only 14-16 months. Mechanisms that lead to chemo- and radio-resistance underpin treatment failure. Insights into the DNA repair mechanisms that permit resistance to chemoradiotherapy in GBM may help improve patient responses to currently available therapies.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Base excision repair; Glioma resistance; MGMT; PARP; Temozolomide chemotherapy

Mesh:

Substances:

Year:  2014        PMID: 25444993     DOI: 10.1016/j.jocn.2014.09.003

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  24 in total

Review 1.  Nanomedicine associated with photodynamic therapy for glioblastoma treatment.

Authors:  Leonardo B de Paula; Fernando L Primo; Antonio C Tedesco
Journal:  Biophys Rev       Date:  2017-08-19

2.  MicroRNA-590-3p enhances the radioresistance in glioblastoma cells by targeting LRIG1.

Authors:  Long Chen; Wenhua Wang; Shengqiang Zhu; Xuegang Jin; Jian Wang; Jianfang Zhu; Youxin Zhou
Journal:  Exp Ther Med       Date:  2017-06-28       Impact factor: 2.447

3.  LRIG1 enhances the radiosensitivity of radioresistant human glioblastoma U251 cells via attenuation of the EGFR/Akt signaling pathway.

Authors:  Ji-An Yang; Bao-Hui Liu; Ling-Min Shao; Zhen-Tao Guo; Qian Yang; Li-Quan Wu; Bao-Wei Ji; Xiao-Nan Zhu; Shen-Qi Zhang; Cheng-Jun Li; Qian-Xue Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

4.  Activation of the Unfolded Protein Response via Inhibition of Protein Disulfide Isomerase Decreases the Capacity for DNA Repair to Sensitize Glioblastoma to Radiotherapy.

Authors:  Yajing Liu; Wenbin Ji; Andrea Shergalis; Jiaqi Xu; Amy M Delaney; Andrew Calcaterra; Anupama Pal; Mats Ljungman; Nouri Neamati; Alnawaz Rehemtulla
Journal:  Cancer Res       Date:  2019-04-17       Impact factor: 12.701

5.  RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma.

Authors:  Ann C Mladek; Huihuang Yan; Shulan Tian; Paul A Decker; Danielle M Burgenske; Katrina Bakken; Zeng Hu; Lihong He; Margaret A Connors; Brett L Carlson; Jonathan Wilson; Archana Bommi-Reddy; Andy Conery; Jeanette E Eckel-Passow; Jann N Sarkaria; Gaspar J Kitange
Journal:  Neuro Oncol       Date:  2022-08-01       Impact factor: 13.029

6.  The expression of miRNA-221 and miRNA-222 in gliomas patients and their prognosis.

Authors:  Liang Xue; Yi Wang; Shuyuan Yue; Jianning Zhang
Journal:  Neurol Sci       Date:  2016-09-15       Impact factor: 3.307

7.  BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair.

Authors:  Shaolu Zhang; Xin Peng; Xiaofei Li; Hongyan Liu; Baoquan Zhao; Moshe Elkabets; Yao Liu; Wei Wang; Ran Wang; Yuxu Zhong; Dexin Kong
Journal:  Cell Death Dis       Date:  2021-05-26       Impact factor: 8.469

Review 8.  Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).

Authors:  Giulio Cabrini; Enrica Fabbri; Cristiana Lo Nigro; Maria Cristina Dechecchi; Roberto Gambari
Journal:  Int J Oncol       Date:  2015-05-29       Impact factor: 5.650

9.  Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review.

Authors:  Neha Singh; Alexandra Miner; Lauren Hennis; Sandeep Mittal
Journal:  Cancer Drug Resist       Date:  2021-03-19

Review 10.  Radioresistance of Brain Tumors.

Authors:  Kevin Kelley; Jonathan Knisely; Marc Symons; Rosamaria Ruggieri
Journal:  Cancers (Basel)       Date:  2016-03-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.